{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+D+%28Blinded+Drug%29&page=2", "query": { "intervention": "Drug D (Blinded Drug)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 41, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+D+%28Blinded+Drug%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+D+%28Blinded+Drug%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T08:26:32.032Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01594320", "title": "A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza (Pandemic)" ], "interventions": [ { "name": "Monovalent Avian Influenza VLP (H5N1)", "type": "BIOLOGICAL" }, { "name": "Monovalent Avian Influenza VLP (H5N1); Adjuvant", "type": "BIOLOGICAL" }, { "name": "Saline placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 333, "start_date": "2012-04", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 5, "location_summary": "Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594320" }, { "nct_id": "NCT06577766", "title": "A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "NNC0638-0355", "type": "DRUG" }, { "name": "Placebo (NNC0638-0355)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 63, "start_date": "2024-09-03", "completion_date": "2027-10-11", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 3, "location_summary": "Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06577766" }, { "nct_id": "NCT00558844", "title": "Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Arikayce™ 560 mg", "type": "DRUG" }, { "name": "Placebo for 560 mg", "type": "DRUG" }, { "name": "Arikayce™ 70 mg", "type": "DRUG" }, { "name": "Arikayce™ 140 mg", "type": "DRUG" }, { "name": "Placebo for 70 mg / 140 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 41, "start_date": "2008-01", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2019-06-04", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00558844" }, { "nct_id": "NCT02328547", "title": "Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Irritable Bowel Syndrome" ], "interventions": [ { "name": "Fecal microbiota transplantation capsules", "type": "DRUG" }, { "name": "Placebo capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "19 Years to 65 Years" }, "enrollment_count": 48, "start_date": "2015-05", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2019-07-02", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 3, "location_summary": "Hamden, Connecticut • New York, New York • The Bronx, New York", "locations": [ { "city": "Hamden", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02328547" }, { "nct_id": "NCT01565850", "title": "D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "D/C/F/TAF", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "D/C/F/TAF Placebo", "type": "DRUG" }, { "name": "DRV Placebo", "type": "DRUG" }, { "name": "COBI Placebo", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2012-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2016-04-11", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01565850" }, { "nct_id": "NCT00208117", "title": "A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Depression", "Coronary Artery Disease (CAD)", "Acute Coronary Syndrome (ACS)" ], "interventions": [ { "name": "Sertraline (Zoloft)", "type": "DRUG" }, { "name": "Simvastatin (Zocor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York State Psychiatric Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 7, "start_date": "2005-04", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2012-05-31", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00208117" }, { "nct_id": "NCT02688270", "title": "Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Raynaud's Phenomenon Secondary to Connective Tissue Disease" ], "interventions": [ { "name": "Vascana (0.9% nitroglycerin cream)", "type": "DRUG" }, { "name": "Vehicle Cream (placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Covis Pharma S.à.r.l.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 65, "start_date": "2016-06", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2022-11-02", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 1, "location_summary": "Multiple Locations, Pennsylvania", "locations": [ { "city": "Multiple Locations", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02688270" }, { "nct_id": "NCT04401579", "title": "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1033, "start_date": "2020-05-08", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401579" }, { "nct_id": "NCT01921010", "title": "Benefit of Elevation of HDL-C in Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cardiovascular Outcomes" ], "interventions": [ { "name": "Niaspan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 43, "start_date": "2003-06", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2019-04-23", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01921010" }, { "nct_id": "NCT01596725", "title": "A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza (Pandemic)" ], "interventions": [ { "name": "Monovalent Avian Influenza VLP (H5N1)", "type": "BIOLOGICAL" }, { "name": "Monovalent Avian Influenza VLP (H5N1); Adjuvant", "type": "BIOLOGICAL" }, { "name": "Saline Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novavax", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 333, "start_date": "2012-05", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-10-08T08:26:32.032Z", "location_count": 5, "location_summary": "Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01596725" } ] }